Syndrome News and Research

RSS

Medical researchers discover structure of potential drug target for rare genetic disease

Medical researchers at the University of Alberta have discovered the structure of a potential drug target for a rare genetic disease, paving the way for an alternative treatment for the condition.

15 Nov 2013

Stem cells from Wolfram syndrome patients used to elucidate beta-cell failure pathway in diabetes

Scientists from the New York Stem Cell Foundation Research Institute and Columbia University Medical Center have used stem cells created from the skin of patients with a rare form of diabetes—Wolfram syndrome—to elucidate an important biochemical pathway for beta-cell failure in diabetes. The findings by Linshan Shang and colleagues were published today in Diabetes.

13 Nov 2013

Researchers recommend strategies to improve overall wellbeing of adults with developmental disabilities

Adults with developmental disabilities such as autism and Down syndrome are having a harder time accessing health care even though they have more health issues than people without developmental disabilities, according to research done at the Institute for Clinical Evaluative Sciences and the Centre for Addiction and Mental Health.

13 Nov 2013

Researchers identify specific IRE1a inhibitor for rheumatoid arthritis treatment

Collaborating with researchers from the Northwestern University Feinberg School of Medicine in Chicago, a research team at Wayne State University's School of Medicine led by Kezhong Zhang, Ph.D., has contributed to an important discovery in the inflammatory stress mechanism and specific inhibitor for the treatment of rheumatoid arthritis.

13 Nov 2013

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye.

13 Nov 2013

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today the completion of patient enrolment for its first clinical trial.

12 Nov 2013

Australian scientists unravel mystery behind immune system memory

While the principle of immune memory has been known for decades, the exact molecular mechanisms underpinning it have remained a mystery. Australian scientists have now unraveled part of that mystery, identifying the role of a gene called STAT3, which acts as a kind of roundabout, directing chemical messenger molecules to various destinations.

12 Nov 2013

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.

12 Nov 2013

Study: Hospitals vary in management of children with traumatic brain injury

Hospitals vary in management of children with traumatic brain injury—particularly in monitoring and preventing the harmful effects of increased intracranial pressure (ICP), according to a study in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

12 Nov 2013

Obesity, overweight are risk factors for MI and IHD regardless of metabolic syndrome

Being overweight or obese are risk factors for myocardial infarction (heart attack) and ischemic heart disease (IHD) regardless of whether individuals also have the cluster of cardiovascular risk factors known as metabolic syndrome, which includes high blood pressure, high cholesterol and high blood sugar, according to a study published by JAMA Internal Medicine, a JAMA Network publication.

12 Nov 2013

LUHS offers highly accurate prenatal test to determine chromosomal abnormalities in fetus

Loyola University Health System (LUHS) now offers chorionic villus sampling (CVS), a highly accurate prenatal test for chromosomal abnormalities in the fetus. Loyola is one of the few centers in the Chicago area to offer CVS.

12 Nov 2013

Metabolic syndrome components signal resistant hypertension

Chinese patients with hypertension that is difficult to treat often have poor cardiometabolic profiles, shows an analysis of the HOT-CHINA study.

11 Nov 2013

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

IVIG is a hugely successful biological with FDA approval for treating idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome, Graves ophthalmopathy and numerous polyneuropathies.

11 Nov 2013

Study: Infants attributed to sudden infant death syndrome may be due to brainstem abnormalities

Investigators at Boston Children's Hospital report that infants dying suddenly and unexpectedly, in both safe and unsafe sleep environments, have underlying brainstem abnormalities and are not all normal prior to death.

11 Nov 2013

Scientists receive $1.2M grants to explore development of AD in individuals with Down syndrome

Donna Wilcock of the University of Kentucky Sanders-Brown Center on Aging is the lead investigator on a recently-funded project exploring the links between Alzheimer's disease and Down Syndrome. Elizabeth Head, also of Sanders-Brown Center on Aging, is a co-investigator on the project.

10 Nov 2013

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

The U.S. Food and Drug Administration today approved the first generic versions of Aciphex (rabeprazole sodium) delayed-release tablets, used to treat gastroesophageal reflux disease in adults and adolescents (ages 12 and up).

10 Nov 2013

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Antibe Therapeutics Inc. is proud to announce that Dr. John Wallace, the Corporation's Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today.

8 Nov 2013

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple.

8 Nov 2013

Aerobic exercise may be superior to resistance exercise for obese teen girls

Obesity has more than doubled in children and tripled in adolescents in the United States in the past 30 years, according to the Centers for Disease Control and Prevention. The growing rate of childhood obesity is a major health concern since overweight and obese youth are at increased risk of developing several diseases once considered reserved for adults. These new pediatric diseases include type-2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease, a condition in which fat builds up in the liver, potentially impairing its function over time.

8 Nov 2013

Study reveals that lower dose of BPA contributes to large range of health problems in humans

Bisphenol A (BPA) is a known endocrine disruptor that hijacks the normal responses of hormones. Yet, traditional toxicology studies indicate that only very high doses of this chemical affect exposed animals-doses as high as 50 mg/kg/day.

8 Nov 2013

Syndrome News and Research

Medical researchers discover structure of potential drug target for rare genetic disease

Stem cells from Wolfram syndrome patients used to elucidate beta-cell failure pathway in diabetes

Researchers recommend strategies to improve overall wellbeing of adults with developmental disabilities

Researchers identify specific IRE1a inhibitor for rheumatoid arthritis treatment

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Australian scientists unravel mystery behind immune system memory

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Study: Hospitals vary in management of children with traumatic brain injury

Obesity, overweight are risk factors for MI and IHD regardless of metabolic syndrome

LUHS offers highly accurate prenatal test to determine chromosomal abnormalities in fetus

Metabolic syndrome components signal resistant hypertension

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

Study: Infants attributed to sudden infant death syndrome may be due to brainstem abnormalities

Scientists receive $1.2M grants to explore development of AD in individuals with Down syndrome

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

Aerobic exercise may be superior to resistance exercise for obese teen girls

Study reveals that lower dose of BPA contributes to large range of health problems in humans

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News